Catalonia In Danger Of Failing Pharma Stability Test
Other companies in the sector could follow Spanish flagship biotech Oryzon and move their headquarters to Madrid, leaving a big hole in the coffers of the Catalan government.
You may also be interested in...
The number of foreign investors participating in Catalan biotech companies has gone from 0 to 50, and over the past five years alone, the figure has increased tenfold, according to the latest Biocat report.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
A few months after bringing AstraZeneca onboard as a partner, the turnaround at the Alderley Park-based firm is moving ahead, buoyed by a fresh financing.